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Highlights 
- Aluminum based adjuvants (ABAs) decrease viability in astrocytes and 
macrophages. 
- Size of aluminum particles influence viability to some extent. 
- Reactive oxygen species formation is consequent to loss of cell viability. 
- After ABA exposure, cytokine production is distinct based on cell type evaluated. 
 
Abstract: 
Aluminum-based adjuvants (ABAs) are used in human vaccines to enhance the 
magnitude of protective immune responses elicited against specific pathogens.  One 
hypothesis is that stress signals released by aluminum-exposed necrotic cells play a role 
in modulating an immune response that contributes to the adjuvant’s effectiveness.  We 
hypothesized that aluminum adjuvant-induced necrosis would be similar irrespective of 
cellular origin or composition of the adjuvant.  To test this hypothesis, human 
macrophages derived from peripheral monocytic cell line (THP-1) and cells derived from 
the human brain (primary astrocytes) were evaluated.  Three commercially available 
formulations of ABAs (Alhydrogel, Imject alum, and Adju-Phos) were examined.  Alum 
was also used as a reference.  Cell viability, reactive oxygen species formation, and 
production of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) were quantified. 
Cells were exposed to different concentrations (10-100 µg/mL) of the adjuvants for 24h 
or 72h.  The two FDA approved adjuvants (Alhydrogel and Adju-Phos) decreased cell 
viability in both cell types.  At the 72h time point, the decrease in viability was 
accompanied with increased ROS formation.  The size of the aluminum agglomerates 
was not relatable to the changes observed.  After exposure to ABAs, astrocytes and 
macrophages presented a distinct profile of cytokine secretion which may relate to the 
function and unique characteristics of each cell type.  These variations indicate that 
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aluminum adjuvants may have differing capability of activating cells of different origin and 
thus their utility in specific vaccine design should be carefully assessed for optimum 
efficacy. 
 
Keywords: Aluminum-Based Adjuvants (ABAs), Macrophages, Astrocytes, Reactive 
Oxygen Species (ROS), Proinflammatory Cytokines 
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Introduction  
 
Vaccination, an important medical procedure initiated in infancy, provides 
immunological protection from a variety of infectious diseases that are encountered in the 
environment. This procedure defends the individual against a myriad of pathogens 
without the necessity of experiencing the infectious disease sequela.  Many vaccines are 
composed of highly purified antigens and require the addition of an adjuvant to provide 
an adequate immune response.  Aluminum-based adjuvants (ABA) have been used since 
1932 and are presently used in more than 30 licensed vaccines (Di Pasquale et al., 2015).  
The types of adjuvants that are available for use in human vaccines include aluminum 
hydroxide gel (Alhydrogel) and an aluminum phosphate gel (Adju-Phos).  Another 
adjuvant, Imject Alum, is available for research and manufacturing but not clinical use 
(Instructions Imject Alum).  Alum is a water soluble aluminum salt composed of aluminum 
potassium sulfate.  It is a reagent that forms the basis of preparation of aluminum-
containing adjuvants (Hem et al., 2007).  In this study, we evaluated all four of these 
aluminum containing salts to determine how the cellular response is affected by dose and 
composition of ABAs or alum.   
Aluminum adjuvants are present in vaccines against hepatitis A, hepatitis B, 
diphtheria-tetanus-pertussis (DTaP), Haemophilus influenzae type b (Hib), human 
papillomavirus (HPV) and pneumococcus infectious agents (Center for Disease Control, 
CDC-2019).  Based on the manufacturer, the type and aluminum content of vaccines 
licensed for use in the United States, varies.  For instance, the Dtap vaccine manufactured 
by GSK (tradename Kinrix) contains ≤0.6 mg of aluminum present as aluminum hydroxide 
while Dtap vaccine manufactured by Sanofi-Pasteur (tradename Daptacel) contains 0.33 
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mg of aluminum present as aluminum phosphate (HogenEsch et al., 2018).  It is thought 
that the amount of aluminum found in these vaccines poses a low risk of harm compared 
to its benefits (Mitkus et al., 2011).  In the present study, we used 10-100 µg/mL 
concentrations which are in the range used by other investigators to assess the in vitro 
response to ABAs (Ulanova et al., 2001; Mold et al., et al., 2016; Vrieling et al., 2020). 
The mechanism by which ABAs strengthen vaccine efficiency is likely to encompass 
multiple pathways (Shi et al., 2019) that lead to a mainly type-2 (humoral) mediated 
immunity (Kuroda et al., 2013).    
A mechanism by which ABAs appear to enhance the efficacy of vaccines is by 
inducing cytotoxicity and the subsequent release of damage associated molecular 
patterns (DAMPs) that activate cellular immune response to the coexisting antigen in the 
vaccine (Kono and Rock, 2008; Marichal et al., 2011).  Previous research demonstrated 
differences in the physiochemical properties of Alhydrogel, Imject Alum, and Adju-Phos 
in regards to their solubility, uptake, and viability using human monocytic (THP-1) cells 
(Mold et al., 2016).  In the present study we further evaluated the response of THP-1 cells 
that were differentiated into macrophages, as well as human astrocytes, exposed to ABAs 
or alum.  We hypothesized that irrespective of adjuvant composition, or tissue derivation 
of cells, ABAs dose-dependently would cause the same degree of necrosis that then 
leads to proinflammatory cytokine release.  Tissue resident macrophages would be 
encountered almost immediately after administration of ABA-containing vaccines.  
Astrocytes on the other hand would be protected by the blood brain barrier.  However, it 
has been proposed that aluminum in vaccines may persist in cells of the immune system 
(such as macrophages) and that these cells can travel to distal sites such as the brain 
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and indirectly impact these tissues (Gherardi et al., 2019).  Astrocytes are immune-
competent resident brain cells that play an important role in homeostatic regulation of the 
brain. We had previously shown that prolonged exposure to low levels of aluminum, 
present in the drinking water, enhances oxidative and inflammatory markers specifically 
in mouse brains (Campbell et al., 2004; Becaria et al., 2006). Furthermore, the 
proinflammatory effect of aluminum was confined to cells of glial origin (Campbell et al., 
1999; Campbell et al., 2002).  In the present study, we aimed to also investigate the 
potential of aggregated forms of aluminum, such as that present in ABAs, to cause an 
oxidative or inflammatory response in brain-derived (astrocytes) in comparison to 
peripherally-derived (macrophages) immune-competent cells. 
Our results suggest that although cell viability was decreased in both cell types, 
accompanied with an increased rate of ROS formation after longer exposures, there was 
a specific profile of cytokine secretion in response to ABA exposure.  Furthermore, the 
composition of the ABAs distinctively influenced the cellular response.  These results 
underscore the importance of careful evaluation of each ABA in specific vaccine design 
to promote the greatest efficacy while avoiding potential adverse effects.  
 
Methods:  
Preparation of Aluminum Adjuvants 
Alhydrogel® adjuvant 2% (catalog #: vac-alu-250, CAS number 21645-51-2) 
composed of aluminum hydroxide gel (aluminum content: 10 mg/mL) and Adju-Phos® 
(catalog #: vac-phos-250, CAS number 7784-30-7) containing aluminum phosphate gel 
(aluminum content: 0.5%), were obtained from InvivoGen (http://www.invivogen.com). 
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Imject® Alum (catalog #: 77161) containing an aqueous solution of aluminum hydroxide 
(40 mg/mL) and magnesium hydroxide (40 mg/mL) was aquired from ThermoFisher 
(Waltham, MA).  Aluminum potassium sulfate dodecahydrate (alum), (product #: 237086-
100G) was from Sigma Aldrich.  
Particle Analysis 
Particle size of the aluminum agglomerates suspended in the media were analyzed 
using the NanoBrook 90Plus particle size analyzer. The effective diameter (nm) and 
dispersity index of the aluminum nanoparticles, in the prepared solutions, were assessed 
(n=3). The suspended dilutions were read at 24h and again at 72h to determine how the 
size of Al gel clusters changed over the duration of cell incubations. 
Exposure 
Macrophages: 
The human monocytic cell line (THP-1) was purchased from ATCC (Manassas, 
VA) and maintained at 37°C in 5% CO2. The cells were grown in RPMI-1640 medium 
(ATCC) containing 0.05 mM 2-mercaptoethanol and 10% fetal bovine serum. THP-1 cells 
were seeded (10,000 cells/well) in a 96-well plate. Cells were incubated with 12-O-
tetradecanoylphorbol-13-acetate (TPA) for 48h to induce differentiation to macrophages 
(Tsuchiya et al., 1982).  Cells were then incubated for 24h or 72h in the absence or 
presence of the prepared aluminum adjuvants (10-100 µg/mL).  
Astrocytes: 
Primary human astrocytes (HA, Catalog #1800) were purchased from ScienCell 
Research Laboratories (Carlsbad, CA) and maintained at 37°C in 5% CO2.  They were 
grown in a proprietary medium obtained from ScienCell (Catalog #1831) consisting of 
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basal medium, fetal bovine serum, growth supplement, and penicillin/streptomysin 
solution.  Cells were grown in poly-L-lysine coated 96-well plates at a density of 10,000 
cells/well. Once seeded, cells were incubated for 48h at 37°C in 5% CO2. Cells were then 
incubated for 24h or 72h with the prepared aluminum adjuvants (10-100 µg/mL).  
Viability Assay 
The cellTiter-Glo luminescent cell viability assay by Promega (Madison, WI) was 
used to evaluate cell viability at the conclusion of the last kinetic reading for ROS 
formation.  The protocol provided by the manufacturer was followed. Briefly, 50 µL of 
CellTiter-Glo® reagent was added to each well.  This was incubated for 10min at room 
temperature and luminescence was measured. The assay quantifies the amount of ATP 
generated in each corresponding well. It can be assumed that the number of viable cells 
is directly proportional to the ATP generated. 
Reactive Oxygen Species (ROS) Formation 
2',7’-dichlorodihydrofluorescein diacetate (DCFH-DA) was used to measure non-
specific ROS formation after ABA exposure. This dye rapidly diffuses into cells and is 
hydrolyzed by intracellular esterases to DCFH and subsequently oxidized to form the 
highly fluorescent dichlorofluorescein (DCF). A DCF standard curve was used to quantify 
ROS formation. BioTek Synergy HT Microplate Reader was used to measure the 
fluorescence generated kinetically for 1h at 10min intervals at an excitation of 485 nm 
and emission of 528 nm.  Results shown are for amount of DCF generated in 30min and 
normalized based on viable cells in corresponding well. 
IL-6 & TNF-α Levels 
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Formation of IL-6 (analytical sensitivity: <2 pg/mL) and TNF-α (analytical 
sensitivity: <0.09 pg/mL) was quantitated using supernatant removed from the treated 
cells. ELISA kits purchased from Invitrogen (Carlsbad, CA) were used to measure Human 
IL-6 or TNF-α in 96 well plates coated with antibodies for the corresponding cytokine in 
accordance with the manufacturer’s protocol. The absorbance was recorded at 450 nm 
using a BioTek Synergy HT Microplate Reader.   
Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism v7.0. Statistical 
significance was determined using one-way ANOVA followed by Dunnett’s post-hoc test.  
Values were considered significant at p ≤ 0.05.  Error bars in figures represent standard 
error of the mean. 
Results  
Particle Analysis 
 In both astrocyte and macrophage media, and at both time points, Adju-Phos 
particles were the largest-sized and alum the smallest based on effective diameter.  The 
dose of the adjuvant did not substantially change the size of the particles except for Adju-
Phos where the higher concentrations tended to coalesce into larger particles (24h: 10 
µg/mL at 2166 ± 72 nm versus 50 µg/mL at 3810 ± 53 nm; 72h: 10 µg/mL at 2180 ± 45 
nm versus 50 µg/mL at 3518 ± 120 nm). This tendency was most pronounced in the 
macrophage medium. Alum particles tend to be smaller in the macrophage medium 
compared to the astrocyte medium (astrocyte medium, 24h: 50µg/mL at 844 ± 64 nm 
versus macrophage medium, 24h: 50 µg/mL at 422 ± 4 nm). The reason for these 
dissimilarities between the macrophage and astrocyte media could be related to the 
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composition of the solutions (see methods section above). The dispersity index for the 
aluminum salts were relatively uniform and small (in the range of 0.073 ± 0.001 - 0.295 ± 
0.076) indicating that the solutions were relatively homogenous.  Incubating the prepared 
aluminum salts at 37°C for 72h did not appear to alter the particle size or the dispersity 
index significantly, indicating that the adjuvants are stable at the time points assessed 
(Table 1).    
Cell Viability  
Macrophages:  After a 24h exposure to ABAs, macrophages exposed to Imject 
had increased levels of ATP compared to control.  This may reflect increased 
mitochondrial activity.  In contrast, Adju-Phos-exposed cells showed severely decreased 
ATP levels which may reflect cell death.  These effects were not dose-dependent.  At the 
72h time point, exposure to both Alhydrogel and Adju-Phos caused a decrease in ATP 
content.  The effects at this time point were dose-dependent.  At 72h exposure, no 
significant change was evident in macrophages exposed to Imject.  At the highest 
concentration of alum, there was an increase in ATP levels (Figure 1).    
Astrocytes: After 24h or 72h exposure to Alhydrogel or Adju-Phos, there was a 
decrease in cell viability.  Imject did not affect cell viability at 24h but after 72h exposure, 
caused cell death at the lower concentrations tested.  Exposure to alum at 24h caused 
an increase after exposure to 20 µg/mL or 50 µg/mL but this was not evident at the 72h 
time point (Figure 2).  
Reactive Oxygen Species (ROS) Formation Jo
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Macrophages:  After a 72h exposure to Alhydrogel or Adju-Phos, there was a dose-
dependent increase in ROS formation. This may have been related to the observed 
decrease in viability.  Imject and alum did not alter ROS formation (Figure 3). 
Astrocytes: After a 24h exposure, there was generally a decline in ROS formation 
after treatment with Imject, alum, or Adju-Phos.   Exposure to Alhydrogel caused no such 
depression.  At the longer 72h time point, exposure to Alhydrogel (50 µg/mL & 100 µg/mL) 
or Adju-Phos (all concentrations), resulted in a consistent increase in ROS formation.  
This was concurrent with and perhaps causal to the decreased cell viability observed at 
this time point. There was an increase in ROS formation only at the 20 µg/mL exposure 
to Imject implying an overall lower level of toxicity of this adjuvant (Figure 4). 
Proinflammatory Cytokine Levels: 
TNF-α: There was a dose dependent increase in the levels of this cytokine in 
macrophages treated with Alhydrogel or Imject.  The levels of TNF-α were increased after 
exposure to both 10 and 50 µg/mL of Adju-Phos (Figure 5). There were no detectable 
levels of this cytokine in the supernatant of the astrocytes treated with any of the 
aluminum adjuvants or alum. 
IL-6:  In macrophages, this cytokine was not detected in the supernatant of control 
or ABA treated (10 µg/mL or 50 µg/mL) samples.  In contrast, the levels of this cytokine 
were markedly increased in supernatants from astrocytes after exposure to all three ABAs 
tested (Alhydrogel ˃ Adju-Phos ˃ Imject).  However, this increase was non-linear and 
most pronounced at lower concentrations (Figure 6).    J
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Discussion  
Global vaccination has reduced the burden of infectious diseases and has led to 
the eradication of smallpox (Greenwood, 2014).  ABAs enhance vaccine effectiveness by 
potentiating immune responses and are widely used because they are cost-effective and 
in general have a good safety profile.  Because of this safety profile, aluminum adjuvants 
are often considered as the “gold standard” against which newly developed adjuvants 
should be compared (HogenEsch et al., 2018).  Studies have shown that there are various 
mechanisms by which ABAs contribute to immunogenicity of vaccines.  One of the best 
studied of these is the role aluminum salts play in adsorption of the inoculated antigen.  
ABAs have the capability of turning the soluble antigens into colloids which can then more 
effectively be internalized, decrease peptide degradation, and enhance MHCII expression 
by antigen-presenting cells (Ghimire et al., 2012).   
Irrespective of antigen binding, ABAs themselves are colloidal and as such are 
capable of orchestrating a cellular immune response regardless of the presence of an 
immunogen (Vrieling et al., 2020). Aluminum hydroxide gel (Alhydrogel) is crystalline, but 
the degree of the structure is based on manufacturing setting and composition of the 
buffers in which it is diluted.  Aluminum phosphate gel (Adju-Phos) is non-crystalline due 
to disruption of the crystallization process by phosphate (HogenEsch et al., 2018).  
Because the composition of the media may have influenced the size of the aluminum 
particles, we evaluated the effective diameter of the aluminum adjuvants in both astrocyte 
and macrophage media for 24h & 72h.  Incubation of alhydrogel in both astrocyte and 
macrophage medium for 24h resulted in formation of particles in the 1048 - 1198 nm 
range at both concentrations tested.  Adju-phos particles were larger (2114 – 3810 nm) 
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and this was concentration-dependent mainly in the macrophage medium.  Imject 
particles were approximately 1288 - 1394 nm in diameter while alum particles were the 
smallest (range of 422 – 844 nm) particularly in the macrophage medium assessed.  With 
increasing incubation time (72h), the size of the aluminum particles did not significantly 
alter.   
After 24h, there was pronounced cytotoxicity observed only after exposure to Adju-
Phos and this may be related to the larger size of the particles.  This is in agreement with 
a study showing that in THP-1 cells, Adju-Phos displayed much greater cytotoxicity 
compared to Alhydrogel (Mold et al., 2016).  Neither alum nor Imject (neither of which are 
used clinically) caused decrease in cell viability in the macrophages. The degree to which 
this finding might influence the effectiveness of Imject as an adjuvant should be further 
investigated.  Both Alhydrogel and Adju-Phos caused a pronounced loss of cell viability 
in macrophages derived from THP-1 cells after a 72h exposure.  No clear relationship 
between particle size and toxicity was observed at this later time point, and thus additional 
physicochemical properties may contribute to loss of cell viability.  Cell viability in 
astrocytes was also decreased to the same extent after exposure to either Alhydrogel or 
Adju-Phos after 24h. Comparing exposure to the two clinically relevant ABAs, the loss of 
viability in astrocytes after 72h was more pronounced after exposure to Adju-Phos, 
especially at the lower concentrations.  Overall, susceptibility of astrocytes did not appear 
to be dose-dependent as the lower concentrations of Adju-Phos (10 & 20 µg/mL) were 
just as capable of reducing viability as the larger doses (50 & 100 µg/mL).  After the 72h 
exposure, both Alhydrogel and Adju-phos caused enhancement of ROS formation 
(especially at the higher doses tested) in both THP-1 derived macrophages and 
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astrocytes.  However, an enhancement of general ROS formation was not observed at 
the 24h time point in the astrocytes. Thus the loss of viability does not appear to be 
associated with oxidative stress, but the cell death appears to contribute to subsequent 
enhancement of oxidative events as judged by an increase in general ROS formation.   
Aluminum adjuvants have been shown to cause cellular necrosis and the 
subsequent production of uric acid, which acts as a threat signal, functions to activate the 
Nlrp3 inflammasome (Eisenbarth et al., 2008). The Nlrp3 inflammasome plays an 
important role in augmenting the inflammatory reaction (Baroja-Mazo et al., 2014) which 
is a mechanism by which ABAs modulate cellular behavior in an immune response.  DNA 
released from ABA-exposed dying cells can also be perceived as a damage associated 
molecular pattern (DAMP) that can modify immunity initiated by aluminum containing 
vaccines (Marichal et al., 2011). A study on the kinetics of the inflammatory response 
induced by ABAs demonstrated that after vaccination, neutrophils are recruited to the 
area followed by macrophages (Lu and HogenEsch, 2013).  Macrophages engulf 
aluminum hydroxide adjuvants, which remain inside the cells as crystal particles, and 
enhance antigen-presentation by the cells (Rimaniol et al., 2004).  
While the changes in viability and ROS formation share similarities in both 
macrophages and astrocytes, ABA induced cytokine responses of the two cell types differ 
sharply.  Macrophages exposed to all three of the aluminum adjuvants show a dose-
dependent increase in TNF-α.  On the other hand, astrocytes exposed to the ABAs 
released significant amounts of IL-6 in a nonmonotonic dose response pattern.  We have 
previously reported that exposure to aluminum sulfate (500µM) for 48h resulted in 
upregulation of oxidative events in glioma but not neuroblastoma cells (Campbell et al., 
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1999), indicating that depending on the type of brain-derived cell evaluated, aluminum 
may cause a specific response.  After a 6d exposure to the same concentration of 
aluminum sulfate, we observed that a human glioblastoma cell line released TNF-α but 
not IL-6 in response to the Al salt (Campbell et al., 2002).  Thus the glioblastoma cell line 
appears to have a cytokine response resembling that of macrophages rather than that of 
primary human astrocytes. Cytokine release in response to aluminum salts may underlie 
the immunomodulatory role of aluminum adjuvants and may be closely related to the 
characteristics and function of the type of cell evaluated.  To what degree these 
differences in cytokine profile may dictate the safety and efficacy of ABAs needs to be 
further investigated. 
Aluminum is a strong phosphate binder and was used for the treatment of 
hyperphosphatemia in dialysis patients before concerns regarding its connection to 
neurological abnormalities led to cessation of its widespread usage (Mudge et al., 2011).  
Chronic aluminum intake from the environment has been considered a potential co-factor 
of several neurological diseases, including Alzheimer’s disease (Campbell et al., 2001; 
Campbell 2002; Bondy and Campbell, 2017).  Chronic exposure to aluminum in the 
drinking water at levels found in some residential water supplies, led to an increase in 
oxidative and inflammatory events that appear specific to the brain (Campbell et al., 2004; 
Becaria et al., 2006).  Therefore, concerns have been raised regarding the safety of 
aluminum adjuvants in individuals who may be predisposed to adverse neurological 
consequences.   
Behavioral abnormalities were detected in mice exposed to clinically relevant 
doses of aluminum hydroxide or the human papillomavirus vaccine, Gardasil, which 
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contains aluminum as an adjuvant (Inbar et al., 2016).  Altered behavior and an increase 
in microglial density was observed in mice exposed to Alhydrogel (Crepeaux et al., 2017).  
In this study, the lowest concentration of aluminum caused the largest effect.  The 
biphasic effect on IL-6 release that we observed in human astrocytes exposed to ABAs 
is concordant with this observation and may in part explain the reason why low 
concentrations of aluminum salts may exert a more selectively neurological response.  
Macrophagic myofasciitis (MMF) is a rare muscle disease that has been linked to ABA 
containing vaccines (Gheradi and Authier, 2012).  This rare condition has also been 
associated with cognitive abnormalities (Aoun Sebaiti et al., 2018).  Elevations of specific 
cytokines have been suggested as markers for MMF (Cadusseau et al., 2014).  
Therefore, while the use of ABAs may provide a very important and useful tool in eliciting 
immunogenicity in vaccines, there may be a select group of individuals who may be 
predisposed to adverse consequences of aluminum-containing vaccines.  For example, 
individuals with autoimmune diseases may over-react to the immunogenicity of ABAs.  
The increase in immune activity would in turn worsen these conditions.   
Conclusion: 
The recent COVID-19 pandemic is a strong reminder that there are genetic 
variations that dictate individual response to the same pathogen.  In severe COVID-19 
cases, there is a cytokine storm that leads to lung damage and eventual death (Shi et al., 
2020).  A similar genetic predisposition to mount an inappropriately strong immune 
response to aluminum particles may predispose a subpopulation of individuals to potential 
adverse health outcomes. While differing cell types may be equally vulnerable to Al salts, 
the consequences of astrocyte injury may be worse than macrophage damage.  This may 
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be reflected by reports that the brain is distinctively vulnerable to low concentrations of 
aluminum salts.  Therefore, in individuals with underlying neurological conditions, the 
risk/benefits of ABA containing vaccines should be evaluated before administration.  
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Figure Legends: 
Figure 1. Cell viability in THP-1 derived macrophages treated with ABAs or alum for 24h 
(A) or 72h (B).  Viability is calculated as percent control from arbitrary units of 
luminescence.  The data presented are a combination of two sets of experiments 
conducted on separate dates (n=8 technical replicates).  Error bars represent the 
standard error of the mean (SEM). *p ≤ 0.05 compared to control group. 
 
Figure 2. Cell viability in human primary astrocytes treated with ABAs or alum for 24h (A) 
or 72h (B).  Viability is calculated as percent control from arbitrary units of luminescence.  
The data presented are a combination of two sets of experiments conducted on separate 
dates (n=8 technical replicates).  Error bars represent the standard error of the mean 
(SEM). *p ≤ 0.05 compared to control group. 
 
Figure 3. Reactive oxygen species formation in THP-1 derived macrophages treated with 
ABAs or alum for 24h (A) or 72h (B).  ROS was calculated as rate of DCF formation in 30 
minutes and converted to %Control.  The data presented are a combination of two sets 
of experiments conducted on separate dates (n=8 technical replicates).  Error bars 
represent the standard error of the mean (SEM). *p ≤ 0.05 compared to control group. 
 
Figure 4. Reactive oxygen species formation in human primary astrocytes treated with 
ABAs or alum for 24h (A) or 72h (B).  ROS was calculated as rate of DCF formation in 30 
minutes and converted to %Control.  The data presented are a combination of two sets 
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of experiments conducted on separate dates (n=8 technical replicates).  Error bars 
represent the standard error of the mean (SEM). *p ≤ 0.05 compared to control group. 
 
Figure 5. Secreted levels of TNF-α in collected media from macrophages treated with 
ABAs or alum (10µg/mL or 50µg/mL) for 24h.  Astrocytes did not produce detectable 
levels of this cytokine. The data presented is n=4 technical replicates conducted in 
duplicates.  Error bars represent the standard error of the mean (SEM). *p ≤ 0.05 
compared to control group. 
 
Figure 6.  
Secreted levels of IL-6 in collected media from astrocytes treated with ABAs or alum 
(10µg/mL or 50µg/mL) for 24h. Macrophages did not produce dettectable levels of the 
cytokine. The data presented is n=4 technical replicates conducted in duplicates.  Error 
bars represent the standard error of the mean (SEM). *p ≤ 0.05 compared to control 
group. 
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Table Legend: 
The effective diameter and dispersity index of aluminum adjuvants or alum (10µg/mL or 
50µg/mL) in astrocyte or macrophage media.  The values were determined after a 24h or 
72h incubation (n=3). 
 
Astrocyte Medium (24h)   Astrocyte Medium (72h) 
Aluminum adjuvant 
Effective 
Diameter (nm) 
Dispersity 
 Index 
Effective 
Diameter (nm) 
Dispersity 
 Index 
Alhydrogel (10 
µg/mL) 1048 ± 4 0.177 ± 0.048 1047 ± 11 0.150 ± 0.027 
Alhydrogel (50 
µg/mL) 1188 ± 4 0.073 ± 0.001 1189 ± 16 0.158 ± 0.015 
IMJECT (10 µg/mL) 1346 ± 17 0.136 ± 0.065 1286 ± 67 0.179 ± 0.016 
IMJECT (50 µg/mL) 1394 ± 69 0.295 ± 0.076 1412 ± 53 0.180 ± 0.066 
ALUM (10 µg/mL) 672 ± 26 0.21 ± 0.004 658 ± 6 0.247 ± 0.024 
ALUM (50 µg/mL) 844 ± 64 0.23 ± 0.023 563 ± 6 0.271 ± 0.006 
Adju-Phos (10 
µg/mL) 2114 ± 42 0.129 ± 0.042 1745 ± 20 0.151 ± 0.69 
Adju-Phos (50 
µg/mL) 2474 ± 44 0.147 ± 0.045 2583 ± 80 0.127 ± 0.48 
Macrophage Medium (24h)   Macrophage Medium (72h) 
Aluminum adjuvant 
Effective 
Diameter (nm) 
Dispersity 
 Index 
Effective 
Diameter (nm) 
Dispersity  
Index 
Alhydrogel (10 
µg/mL) 1057 ± 11 0.235 ± 0.006 1332 ± 15 0.107 ± 0.041 
Alhydrogel (50 
µg/mL) 1198 ± 22 0.167 ± 0.071 1152 ± 16 0.151 ± 0.033 
IMJECT (10 µg/mL) 1288 ± 42 0.185 ± 0.042 1222 ± 74 0.174 ± 0.025 
IMJECT (50 µg/mL) 1382 ± 58 0.142 ± 0.030 1555 ± 10 0.126 ± 0.062 
ALUM (10 µg/mL) 435 ± 4 0.250 ± 0.013 404 ± 5 0.213 ± 0.017 
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ALUM (50 µg/mL) 422 ± 4 0.283 ± 0.015 413 ± 4 0.286 ± 0.017 
Adju-Phos (10 
µg/mL) 2166 ± 72 0.143 ± 0.046 2180 ± 45 0.128 ± 0.055 
Adju-Phos (50 
µg/mL) 3810 ± 53 0.178 ± 0.171 3518 ± 120 0.259 ± 0.014 
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